SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) incurred a loss of 54 cents per share in the second quarter of 2024, which was significantly narrower than the Zacks Consensus Estimate of a loss of $1.12. The company had reported a loss of $1.25 per share in the year-ago quarter. In the second quarter, total revenues were $59.7 million, which also comprehensively beat the Zacks Consensus Estimate of $35 million. Total revenues comprised net product sales of Ogsiveo (nirogacestat) and other revenues. The company did not generate any revenues in the year-ago quarter. Ogsiveo was approved by the FDA…